Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV


Delayed Quote. Delayed Nyse - 10/30 04:10:00 pm
85.1 USD   +5.49%
11:43aGLOBAL MARKETS LIVE : Alphabet, Amazon, Starbucks…
10:22aWall St slumps as tech stocks slide, COVID cases jump
09:51aABBVIE : Correction to AbbVie Earnings Article
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie : Completes Transformative Acquisition of Allergan

share with twitter share with LinkedIn share with facebook
05/11/2020 | 11:33am EDT

NORTH CHICAGO - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.

'We are pleased to reach this important milestone for the Company, its employees, shareholders and the patients we serve,' said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. 'Our new Allergan colleagues should be commended for all their efforts, along with those of our own employees, to achieve this turning point for our Company. The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets, and our financial strength will allow us to continue to invest in innovative science and continue to serve unmet medical needs of patients that rely upon us. I am proud of both organizations and look forward to the opportunities ahead.'

Well-Positioned for Long-Term Growth in Key Therapeutic Areas

The transaction significantly expands and diversifies AbbVie's revenue base and complements existing leadership positions in Immunology, with Humira, and recently launched Skyrizi and Rinvoq, and Hematologic Oncology, with Imbruvica and Venclexta. Allergan provides new growth opportunities in Neuroscience, with Botox Therapeutics, Vraylar and Ubrelvy and a global aesthetics business, with leading brands including Botox and Juvederm.

This diversified on-market portfolio will drive the existing AbbVie growth platform (ex-Humira) to approximately $30 billion in revenues in full year 2020, with combined revenues of approximately $50 billion. It also positions the Company for enhanced long-term growth potential, a growing dividend and investment in innovation in each of its therapeutic categories. The Company anticipates rapidly paying down the incremental debt with its increased operating cash flows.

Additionally, in connection with the closing of the transaction, the AbbVie Board of Directors has elected Thomas C. Freyman, retired Executive Vice President and Chief Financial Officer, Abbott, to join the AbbVie board. Mr. Freyman recently served on the Allergan Board of Directors.

Financial Terms

Under the terms of the transaction agreement, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total consideration of $193.23 per Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020). Allergan common stock ceased trading on the New York Stock Exchange as of the close of trading today.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Forward-Looking Statements

This announcement contains certain forward-looking statements, including with respect to AbbVie's acquisition of Allergan (the 'acquisition') and the combined group's estimated or anticipated future business, performance and results of operations and financial condition, including estimates, forecasts, targets and plans for the combined group. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions, among others, generally identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits of the acquisition, including the synergies and value creation contemplated by the acquisition, failure to promptly and effectively integrate Allergan's businesses, negative effects relating to the consummation of the acquisition on the market price of AbbVie's shares of common stock, significant transaction costs and/or unknown or inestimable liabilities, potential litigation associated with the acquisition, the combined group's inability to retain key personnel, general economic and business conditions that affect the combined group, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business acquisitions or disposals, competitive developments and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie's experience and perception of historical trends, current conditions, business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this announcement could cause AbbVie's plans with respect to Allergan or AbbVie's actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this announcement are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this announcement. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie is set forth in AbbVie's periodic public filings with the U.S. Securities and Exchange Commission, including, but not limited to, AbbVie's Annual Report on Form 10-K for the year ended December 31, 2019 as updated by its subsequent Quarterly Reports on Form 10-Q, and, from time to time, AbbVie's other investor communications, in each case, the contents of which are not incorporated by reference into, nor do they form part of, this announcement.

Any forward-looking statements in this announcement are based upon information available to AbbVie and/or its board of directors as of the date of this announcement and, while believed to be true when made, may ultimately prove to be incorrect. All subsequent written and oral forward-looking statements attributable to AbbVie or its board of directors or any person acting on behalf of them are expressly qualified in their entirety by this paragraph.


Adelle Infante

Tel: (847) 938-8745

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 5.49% 85.1 Delayed Quote.-3.89%
ALLERGAN PLC 0.02% 193.02 Delayed Quote.0.97%
share with twitter share with LinkedIn share with facebook
All news about ABBVIE INC.
11:43aGLOBAL MARKETS LIVE : Alphabet, Amazon, Starbucks…
10:22aWall St slumps as tech stocks slide, COVID cases jump
09:51aABBVIE : Correction to AbbVie Earnings Article
08:23aABBVIE : Logs 3Q Sales Growth on Higher Immunology, Oncology Results
07:57aABBVIE : 3Q Earnings Snapshot
07:54aABBVIE INC. : Results of Operations and Financial Condition, Financial Statement..
10/29ABBVIE : Highlights Innovative Research for People with Rheumatic Diseases with ..
10/29ABBVIE : Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results..
10/29ABBVIE : to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ ..
10/28ABBVIE : Allergan Presbyopia Treatment Hits Main Endpoint in Phase 3 Studies
More news
Financials (USD)
Sales 2020 45 519 M - -
Net income 2020 6 919 M - -
Net Debt 2020 74 016 M - -
P/E ratio 2020 21,8x
Yield 2020 5,80%
Capitalization 142 B 142 B -
EV / Sales 2020 4,75x
EV / Sales 2021 3,86x
Nbr of Employees 47 000
Free-Float 98,5%
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 20
Average target price 109,25 $
Last Close Price 85,10 $
Spread / Highest target 49,2%
Spread / Average Target 28,4%
Spread / Lowest Target 12,8%
EPS Revisions
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.-3.89%142 369
JOHNSON & JOHNSON-5.95%361 159
ROCHE HOLDING AG-6.40%274 461
PFIZER INC.-9.95%196 047
MERCK & CO., INC.-16.56%191 944
NOVARTIS AG-22.62%176 518